Prescription Drug Supply Chain Pricing Transparency Act

Plain-English Summary: Prescription Drug Supply Chain Pricing Transparency Act

This bill, introduced in the Senate, aims to shed light on how prescription drug prices are set and how money moves through the complex chain of companies involved in getting medications from manufacturers to patients. Currently, the pricing process involves multiple middlemen — including drug makers, wholesalers, pharmacies, and pharmacy benefit managers (PBMs) — and much of how they negotiate prices and fees happens behind closed doors. This legislation would require greater disclosure of pricing information at various points along that supply chain.

The bill would likely affect a wide range of players in the healthcare system, including pharmaceutical companies, PBMs (the companies that manage prescription drug benefits for insurers and employers), insurance plans, and pharmacies. By requiring these entities to report or disclose more information about the prices they charge, the fees they collect, and the rebates they receive, the bill tries to make it easier to understand why patients and insurers end up paying what they do for medications.

Everyday Americans — particularly those who pay high out-of-pocket costs for prescription drugs — could potentially benefit if greater transparency leads to more accountability and competitive pricing in the market. Employers who provide health insurance to workers could also gain clearer insight into where their money goes. However, because the bill has only been introduced and referred to the Senate Finance Committee, it is still in the very early stages of the legislative process and has not yet become law.